Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Stimulating effect of normal-dosing of fibrates on cell proliferation: word of warning

K. Cizkova, J. Steigerova, J. Gursky, J. Ehrmann

. 2016 ; 15 (1) : 164. [pub] 20160922

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22007953

Grantová podpora
NV15-30585A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Fibrates are widely used hypolipidemic drugs, which serve as ligand of peroxisome proliferator-activated receptor α (PPARα). Recently, they have also been considered as potential anticancer agents. We studied effect of fibrates treatment on cell proliferation, expression of CYP2J2 and concomitant changes in expression of cell cycle regulatory proteins in three different human cell lines: HEK293, HepG2, and HT-29. METHODS: We used WST-1 viability test, western blot and immunocytochemistry for detection of proteins of interests and analysis of cell cycle. RESULTS: Our results showed that at lower concentrations of all tested fibrates, viability of all tested cell lines is increased, whereas at higher concentrations, repression is apparent. Unfortunately, the viability of tested cells is predominantly increased in a range of concentration which is reached in patient plasma. This phenomenon is accompanyed by elevation of CYP2J2, increased number of cyclin E-positive cells and decreased number of Cdc25A-positive cells in all tested cell lines, and elevated cyclin A expression in HepG2 and HT-29. These changes are concentration-dependent. We suppose that increased level of CYP2J2 could explain enhanced cell proliferation in lower concentration of fibrates. CONCLUSION: Based on our results, we suggested there is no anti-cancer effect of fibrates in tested carcinoma cell lines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22007953
003      
CZ-PrNML
005      
20230111093222.0
007      
ta
008      
220309s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12944-016-0335-z $2 doi
035    __
$a (PubMed)27658584
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Čížková, Kateřina $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic. keri@email.cz $7 xx0249672
245    10
$a Stimulating effect of normal-dosing of fibrates on cell proliferation: word of warning / $c K. Cizkova, J. Steigerova, J. Gursky, J. Ehrmann
520    9_
$a BACKGROUND: Fibrates are widely used hypolipidemic drugs, which serve as ligand of peroxisome proliferator-activated receptor α (PPARα). Recently, they have also been considered as potential anticancer agents. We studied effect of fibrates treatment on cell proliferation, expression of CYP2J2 and concomitant changes in expression of cell cycle regulatory proteins in three different human cell lines: HEK293, HepG2, and HT-29. METHODS: We used WST-1 viability test, western blot and immunocytochemistry for detection of proteins of interests and analysis of cell cycle. RESULTS: Our results showed that at lower concentrations of all tested fibrates, viability of all tested cell lines is increased, whereas at higher concentrations, repression is apparent. Unfortunately, the viability of tested cells is predominantly increased in a range of concentration which is reached in patient plasma. This phenomenon is accompanyed by elevation of CYP2J2, increased number of cyclin E-positive cells and decreased number of Cdc25A-positive cells in all tested cell lines, and elevated cyclin A expression in HepG2 and HT-29. These changes are concentration-dependent. We suppose that increased level of CYP2J2 could explain enhanced cell proliferation in lower concentration of fibrates. CONCLUSION: Based on our results, we suggested there is no anti-cancer effect of fibrates in tested carcinoma cell lines.
650    17
$a proliferace buněk $7 D049109 $2 czmesh
650    17
$a deriváty kyseliny fibrové $x analýza $7 D058607 $2 czmesh
650    _7
$a cytochrom P-450 CYP2J2 $7 D000090762 $2 czmesh
650    _7
$a HEK293 buňky $7 D057809 $2 czmesh
650    _7
$a buňky Hep G2 $7 D056945 $2 czmesh
650    _7
$a buňky HT-29 $7 D019073 $2 czmesh
650    _7
$a PPAR alfa $x analýza $7 D047493 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
655    _2
$a časopisecké články $7 D016428
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Steigerová, Jana, $u Department of Clinical and Molecular Pathology & Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic $d 1979- $7 xx0142054
700    1_
$a Gursky, Jan $u Institute of Molecular and Translation Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 775 15, Olomouc, Czech Republic
700    1_
$a Ehrmann, Jiří, $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, 775 15, Olomouc, Czech Republic $u Department of Clinical and Molecular Pathology & Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic $d 1967- $7 jo2003163162
773    0_
$w MED00008241 $t Lipids in health and disease $x 1476-511X $g Roč. 15, č. 1 (2016), s. 164
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27658584 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220309 $b ABA008
991    __
$a 20230111093217 $b ABA008
999    __
$a kom $b bmc $g 1768239 $s 1159146
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 15 $c 1 $d 164 $e 20160922 $i 1476-511X $m Lipids in health and disease $n Lipids Health Dis $x MED00008241
GRA    __
$a NV15-30585A $p MZ0
LZP    __
$c NLK120 $d 20230111 $a 2021-granty

Najít záznam

Citační ukazatele

Možnosti archivace